Alcaide F, Liñares J, Pallares R, Carratala J, Benitez M A, Gudiol F, Martin R
Service of Microbiology, Hospital Prínceps d'Espanya, Ciutat Sanitària i Universitària de Bellvitge, Barcelona, Spain.
Antimicrob Agents Chemother. 1995 Oct;39(10):2243-7. doi: 10.1128/AAC.39.10.2243.
A total of 410 strains of viridans group streptococci isolated consecutively from blood were tested by the microdilution method for in vitro susceptibility to 22 beta-lactam antibiotics. One hundred thirty-eight strains (33.6%) were resistant to penicillin with a MIC range of 0.25 to 8 micrograms/ml. MICs of all beta-lactam agents tested were higher for penicillin-resistant strains than for susceptible strains. These antibiotics were classified into three groups according to their in vitro activities (MICs at which 50 and 90% of the isolates are inhibited). Beta-Lactams of the first group (these included imipenem, cefpirome, FK-037, cefditoren, cefotaxime, ceftriaxone, and cefepime) showed activities higher than or similar to that of penicillin against penicillin-resistant viridans group streptococci. However, 80% of highly penicillin-resistant Streptococcus mitis organisms required cefotaxime and ceftriaxone MICs of > or = 2 micrograms/ml (range, 2 to 16 micrograms/ml). Beta-Lactams of the second group (cefpodoxime, ampicillin, amoxicillin-clavulanate, piperacillin, and cefuroxime) showed lower activities than penicillin. Finally, antibiotics of the third group (cephalothin, oxacillin, ceftazidime, cefixime, cefaclor, cefetamet, cefadroxil, cephalexin, and ceftibuten) showed poor in vitro activities. Therefore, some of the beta-lactam agents included in the first group could be an acceptable alternative in the treatment of serious infections due to strains highly resistant to penicillin, although clinical experience is needed.
采用微量稀释法对连续从血液中分离出的410株草绿色链球菌进行了22种β-内酰胺类抗生素的体外药敏试验。138株(33.6%)对青霉素耐药,其MIC范围为0.25至8微克/毫升。所有受试β-内酰胺类药物对青霉素耐药菌株的MIC均高于敏感菌株。根据其体外活性(抑制50%和90%分离株的MIC),这些抗生素被分为三组。第一组β-内酰胺类药物(包括亚胺培南、头孢匹罗、FK-037、头孢妥仑、头孢噻肟、头孢曲松和头孢吡肟)对青霉素耐药的草绿色链球菌显示出高于或类似于青霉素的活性。然而,80%的对青霉素高度耐药的缓症链球菌菌株需要头孢噻肟和头孢曲松的MIC≥2微克/毫升(范围为2至16微克/毫升)。第二组β-内酰胺类药物(头孢泊肟、氨苄西林、阿莫西林-克拉维酸、哌拉西林和头孢呋辛)显示出比青霉素更低的活性。最后,第三组抗生素(头孢噻吩、苯唑西林、头孢他啶、头孢克肟、头孢克洛、头孢他美、头孢羟氨苄、头孢氨苄和头孢布烯)显示出较差的体外活性。因此,尽管需要临床经验,但第一组中的一些β-内酰胺类药物可作为治疗对青霉素高度耐药菌株引起的严重感染的可接受替代药物。